Related Links
Statistics
| Number of Journals | 8 |
| Number of Issues | 60 |
| Number of Articles | 447 |
| Article View | 170,251 |
| PDF Download | 113,879 |
Targeting oxidized sGC in calcific aortic valve stenosis: a narrative review of ataciguat | ||
| Cardiovascular Biomedicine | ||
| Volume 5, Issue 2, December 2025, Pages 13-32 PDF (672.59 K) | ||
| Document Type: review article | ||
| DOI: 10.18502/cbj.v5i2.21133 | ||
| Authors | ||
| Farid Taghavi1; Shirin Alord2; Somayyeh Mehanfar1; Kamran Mohammadi* 1 | ||
| 1Cardiovascular Research Center, Department of Cardiology, Tabriz University of Medical Sciences, Tabriz, Iran | ||
| 2Cardiovascular Research Center, Health Policy and Promotion Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran | ||
| Abstract | ||
| Objectives: No pharmacologic treatment has been shown to slow the course of calcific aortic valve stenosis (CAVS), an active fibrocalcific disease. A downstream signaling bottleneck in the NO–sGC–cyclic guanosine monophosphate (cGMP) pathway is created when oxidative stress transforms soluble guanylate cyclase (sGC) into nitric oxide (NO)–insensitive, oxidized/heme-free states. With an emphasis on the NO-independent sGC activator ataciguat (HMR-1766), this narrative review aims to highlight the molecular, translational, and clinical evidence supporting oxidized/heme-free sGC as a therapeutic target in CAVS. Methods: We conducted a structured narrative literature search across PubMed/MEDLINE, Embase, Web of Science, Scopus, Cochrane Central, and trial registries (ClinicalTrials.gov/WHO ICTRP) through October 19, 2025. We prioritized original mechanistic/structural studies, preclinical pharmacology, valve-biology investigations, and human translational/clinical studies evaluating ataciguat, sGC redox biology, and disease-modification endpoints (e.g., CT-derived aortic valve calcium [CT-AVC] and ^18F-NaF PET). Results: Across structural and biochemical studies, heme-mimetic sGC activators selectively bind oxidized/heme-free sGC and restore cGMP signaling by occupying the heme pocket, thereby bypassing NO insensitivity. Valve-biology studies indicate that NO–sGC–cGMP signaling and NO-dependent S-nitrosylation/NOTCH pathways function as complementary anti-calcific mechanisms linked to shear stress and endothelial integrity. Imaging biomarkers such as CT-AVC and ^18F-NaF PET provide sensitive readouts of calcification burden and activity. Early randomized clinical evidence in moderate CAVS suggests oral ataciguat is generally well tolerated and is associated with a directional slowing of CT-AVC progression over six months. Conclusions: All currently available information suggests that oxidized/heme-free sGC is a biologically reasonable and treatable target in CAVS. Ataciguat exhibits early human signs of delayed calcific development and redox-selective restoration of NO–cGMP signaling. To verify long-term structural advantages and clinical impact, however, longer-term, well-powered clinical investigations are needed. | ||
| Keywords | ||
| Calcific aortic valve stenosis; soluble guanylate cyclase; oxidized sGC; heme-free sGC; ataciguat (HMR-1766); cyclic GMP | ||
| References | ||
|
1. Otto CM, Newby DE, Hillis GS. Calcific Aortic Stenosis: A Review. JAMA. 2024;332(23):2014- 2026.
2. Zhang B, Enriquez-Sarano M, Schaff HV, et al. Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy. Circulation. 2025;151(13):913–930.
3. Arsenault BJ, Loganath K, Girard A, et al. Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis. JAMA Cardiol. 2024;9(9):835–842.
4. Lan NSR, Khan Z, Watts GF. Lipoprotein(a) and calcific aortic valve disease: current evidence and future directions. Curr Opin Clin Nutr Metab Care. 2024;27(1):77–86.
5. Tsimikas S. Lp(a) and Accelerated Progression of Aortic Stenosis: A Rationale for Universal Measurement and Therapeutic Targeting. JACC Asia. 2024;4(10):761–763.
6. Doris MK, Jenkins W, Robson P, et al. Computed tomography aortic valve calcium scoring for the assessment of aortic stenosis progression. Heart. 2020;106(24):1906–1913.
7. Scalia IG, Farina JM, Padang R, et al. Aortic Valve Calcium Score by Computed Tomography as an Adjunct to Echocardiographic Assessment-A Review of Clinical Utility and Applications. J Imaging. 2023;9(11): 250.
8. Majumdar U, Manivannan S, Basu M, et al. Nitric oxide prevents aortic valve calcification by S-nitrosylation of USP9X to activate NOTCH signaling. Sci Adv. 2021;7(6): eabe3706.
9. Shah RC, Sanker S, Wood KC, et al. Redox regulation of soluble guanylyl cyclase. Nitric Oxide. 2018;76:97–104.
10. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263–73.
11. Lindman BR, Sukul D, Dweck MR, et al. Evaluating Medical Therapy for Calcific Aortic Stenosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78(23):2354–2376.
12. Bhakta S, Chowdhury MM, Tarkin JM, et al. (18)F-NaF uptake on vascular PET imaging in symptomatic versus asymptomatic atherosclerotic disease: A meta-analysis. Vasc Med. 2025;30(1):10–19.
13. Nossaman B, Pankey E, Kadowitz P. Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. Crit Care Res Pract. 2012;2012:290805.
14. Kollau A, Opelt M, Wölkart G, et al. Irreversible Activation and Stabilization of Soluble Guanylate Cyclase by the Protoporphyrin IX Mimetic Cinaciguat. Mol Pharmacol. 2018;93(2):73–78.
15. Surmeli NB, Marletta MA. Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat. Chembiochem. 2012;13(7):977–81.
16. Martin F, Baskaran P, Ma X, et al. Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J Biol Chem. 2010;285(29):22651–7.
17. Zhou Z, Pyriochou A, Kotanidou A, et al. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol. 2008;295(4):H1763–71.
18. Schäfer A, Flierl U, Kobsar A, et al. Soluble Guanylyl Cyclase Activation With HMR1766 Attenuates Platelet Activation in Diabetic Rats. Arterioscler, Thromb Vasc Biol. 2006;26(12):2813–8.
19. Weissmann N, Hackemack S, Dahal BK, et al. The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2009;297(4):L658–L65.
20. Oberwittler H, Hirschfeld-Warneken A, Wesch R, et al. Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. J Clin Pharmacol. 2007;47(1):70–7.
21. Bosse K, Hans CP, Zhao N, et al. Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease. J Mol Cell Cardiol. 2013;60:27–35.
22. Richards J, El-Hamamsy I, Chen S, et al. Side-specific endothelial-dependent regulation of aortic valve calcification: interplay of hemodynamics and nitric oxide signaling. Am J Pathol. 2013;182(5):1922–31.
23. Farrar EJ, Huntley GD, Butcher J. Endothelial-Derived Oxidative Stress Drives Myofibroblastic Activation and Calcification of the Aortic Valve. PloS One. 2015;10(4):e0123257.
24. Dweck MR, Jenkins WS, Vesey AT, et al. 18F-sodium fluoride uptake is a marker of active calcification and disease progression in patients with aortic stenosis. Circ Cardiovasc Imaging. 2014;7(2):371–8.
25. Pawade TA, Cartlidge TR, Jenkins WS, et al. Optimization and Reproducibility of Aortic Valve 18F-Fluoride Positron Emission Tomography in Patients With Aortic Stenosis. Circ Cardiovasc Imaging. 2016;9(10):e005131.
26. Murtazalieva P, Ryzhkova D, Malev E, et al. Prediction of Aortic Stenosis Progression by (18)F-FDG and (18)F-NaF PET/CT in Different Aortic Valve Phenotypes. Front Pharmacol. 2022;13:909975.
27. Lassen ML, Tzolos E, Massera D, et al. Aortic valve imaging using (18)F-sodium fluoride: impact of triple motion correction. EJNMMI Phys. 2022;9(1):4.
28. Lapp H, Mitrovic V, Franz N, et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009;119(21):2781–8.
29. Zhou Z, Pyriochou A, Kotanidou A, et al. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol. 2008;295(4):H1763–71.
30. Weissmann N, Hackemack S, Dahal BK, et al. The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2009;297(4):L658–65.
31. Eley L, Richardson RV, Alqahtani A, et al. eNOS plays essential roles in the developing heart and aorta linked to disruption of Notch signalling. Dis Model Mech. 2024;17(1):dmm050265.
32. Majumdar U, Choudhury TZ, Manivannan S, et al. Single-cell RNA-sequencing analysis of aortic valve interstitial cells demonstrates the regulation of integrin signaling by nitric oxide. Front Cardiovasc Med. 2022;9:742850.
33. Massera D, Doris MK, Cadet S, et al. Analytical quantification of aortic valve 18F-sodium fluoride PET uptake. J Nucl Cardiol. 2020;27(3):962–972.
34. Lassen ML, Tzolos E, Massera D, et al. Aortic valve imaging using 18F-sodium fluoride: impact of triple motion correction. EJNMMI Physics. 2022;9(1):4.
35. Cecelja M, Moore A, Fogelman I, et al. Evaluation of aortic (18)F-NaF tracer uptake using PET/CT as a predictor of aortic calcification in postmenopausal women: A longitudinal study. JRSM Cardiovasc Dis. 2019;8:2048004019848870.
36. Schmidt HH, Schmidt PM, Stasch JP. NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol. 2009(191):309–39.
37. Hoffmann LS, Schmidt PM, Keim Y, et al. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. Br J Pharmacol. 2009;157(5):781–95.
38. Næsheim T, How OJ, Myrmel T. Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs. J Cardiovasc Pharmacol Ther. 2021;26(1):75–87. | ||
|
Statistics Article View: 25 PDF Download: 24 |
||